Fibroz pecheni: vozmozhnosti obratnogo razvitiya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Liver fibrosis (LF) is a typical pathological process underlying virtually any diffuse chronic liver disease, regardless of its etiology. The mechanisms of LF and criteria for its diagnosis are presented. Reversibility of LF, including in chronic viral liver diseases, is proved. It is emphasized that modern scientific achievements in the field of LF form the basis to search for new effective antifibrotic therapies.

Full Text

Restricted Access

References

  1. Popper H. Present day morphology of cirrhosis. Gastroenterology 1958;34(4):661-66.
  2. Popper H. Kent G. Fibrosis in chronic liver disease. Clin Gastroenterol 1975;4(2):315-32.
  3. Soyer MT, Ceballos R, Aldrete JS. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 1976;79(5):601-04.
  4. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-85.
  5. Wake K "Sternzellen" in the liver: perisinusoidalcells with special reference to storage of vitamin A. Am J Anat 1971;132:429-62.
  6. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38( 1 ):38-53.
  7. Pinzani M, Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008; 12(4):901-13.
  8. Snowdon VK, Fallowfield JA. Models and mechanisms of fibrosis resolution. Alcohol Clin Exp Res 2011;35(5):794-99.
  9. Brenner DA, Seki E, Taura K, et al. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res 2011 ;41(7):683-86.
  10. Roderfeld M, Koc A, Rath T, at al. Induction of matrix metalloproteinases and TLR2 and 6 in murine colon after oral exposure to Mycobacterium avium subsp. Paratuberculosis. Microbes Infect 2012; 14(6):545-53.
  11. Wang H, Lafdil F, Wang L, et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci 2011;1(1):14.
  12. Povero D, Busletta C, Novo E, et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010;25(8):1075-91.
  13. Bedossa P, Poynard T. An algorhythm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289-93.
  14. Yamanaka N, Okamoto E, Toyosaka A, et al. Consistency of human liver. J Surg Res 1985;39:192-98.
  15. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
  16. Yeh WC, Li PC, Jeng YM, et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol 2002;28:467-74.
  17. Brunt ME. Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond. Hepatology 2000;31(1 ):241 -46.
  18. Лазебник Л.Б., Винницкая Е.В., Хомерики С.Г. и др. Фиброэластометрия печени у пожилых // Эксперим. и клин. гастроэнтерол. 2010. № 12. С. 24-6.
  19. Винницкая Е.В. Место ультразвуковой эластометрии в диагностике хронических болезней печени / Материалы VII московской ассамблеи "Здоровье столицы", 18-19.12.2008. М., 2008. С. 152-53.
  20. Rosenberg WM, Voelker M, Thiel R, et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127(6):1704-13.
  21. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010;9( 10): 103.
  22. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73.
  23. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3): 678-86.
  24. Chang TT, Liaw Y-F, Wu SS, et al. Long-term entecavir therapy results in reversal of fibrosis/ cirrhosis and continued histologic improvement in patients with chronic hepatitis B. Hepatology 2010; 52(3);886-93.
  25. Shiff ER, Lee SS,Chao Y-C, et al. Длительное лечение энтекавиром вызывает обратное развитие выраженного фиброза и цирроза у больных хроническим гепатитом В // Клин. гастроэнтерол. гепатол. Русское издание. 2011. № 1. С. 10-3.
  26. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010; 152(3): 159-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies